Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not ...

17 In patients with treatment-resistant depression, reductions in depressive symptoms and in the risk of relapse were observed with esketamine nasal spray as compared with placebo nasal spray when ...

A nasal spray version of esketamine was more effective for depression that is resistant to treatment than a more commonly used drug, research published Wednesday in The New England Journal of ...

Fast-acting antidepressants can work in hours to help you feel better if you have depression or suicidal thoughts. The FDA in 2019 approved the first, a nasal spray called esketamine for treatment ...

However, Spravato (esketamine) is a patented nasal spray that contains only the S-ketamine molecule. Spravato has been approved by the FDA for adults with treatment-resistant depression since 2019.

More information: Antonio Del Casale et al, Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression, JAMA Psychiatry (2025). DOI: 10.1001/jamapsychiatry.2025.0200 ...

A 67-year-old woman with a history of obesity, chronic low back pain, and recurrent episodes of major depression presents ... and ketamine or esketamine therapy) when depressive symptoms are ...

A nasal spray formulation is authorized under certain conditions for the treatment of resistant depression. Several studies have shown that small doses of esketamine improve analgesia and reduce ...

To examine this further, researchers based in China and the U.S. wanted to find out if a single low dose injection of esketamine given just after childbirth might reduce subsequent depression in ...

Esketamine targets the glutamate neurotransmitter pathway, offering a novel mechanism for treatment-resistant depression. The treatment is available through a Risk Evaluation and Mitigation ...

The drug is now cleared for use as a standalone treatment for depression. Spravato is made from esketamine, one of two mirror-image molecules found in the anesthetic ketamine. It was approved in ...